[Effects of GSK3β/eEF2K signaling pathway on pulmonary fibrosis in mice]

Chao-Qun Qin1, Bin Huang1, Fang Yang1

  • 1Guilin People's Hospital, Guilin 541002, China.

Insights

This study reveals that glycogen synthase kinase-3β (GSK3β) activates eukaryotic extension factor kinase 2 (eEF2K), promoting pulmonary fibrosis. Inhibiting this pathway reduces fibrosis indicators and lung damage, offering new therapeutic targets for pulmonary fibrosis.

Area of Science:

  • Pulmonary Medicine
  • Cellular Signaling
  • Fibrosis Research

Background:

  • Pulmonary fibrosis is a progressive lung disease with limited treatment options.
  • The role of the glycogen synthase kinase-3β (GSK3β)/eukaryotic extension factor kinase 2 (eEF2K) signaling pathway in pulmonary fibrosis is not fully understood.

Purpose of the Study:

  • To investigate the involvement of the GSK3β/eEF2K signaling pathway in pulmonary fibrosis.
  • To explore potential therapeutic strategies targeting this pathway for pulmonary fibrosis treatment.

Main Methods:

  • A bleomycin-induced pulmonary fibrosis mouse model was established.
  • Mice were treated with TDZD-8, a GSK3β inhibitor.
  • Lung fibrosis was assessed using Hematoxylin-eosin staining and Ashcroft scoring.
  • Protein expression levels of GSK3β, p-GSK3β, eEF2K, p-eEF2K, pro-MMP-2, MMP-2, collagen I, collagen III, and α-SMA were analyzed via Western blot.

Main Results:

  • Bleomycin induced significant pulmonary fibrosis, characterized by increased fibrosis scores and elevated expression of fibrosis markers.
  • GSK3β activation correlated with increased phosphorylation of eEF2K at Ser70, Ser392, and Ser470.
  • Inhibition of GSK3β with TDZD-8 reduced fibrosis scores and suppressed the expression of fibrosis-related proteins, including MMP-2, collagen I, collagen III, and α-SMA.
  • TDZD-8 treatment also increased eEF2K expression while decreasing its phosphorylation, suggesting a feedback mechanism.

Conclusions:

  • GSK3β activates eEF2K through phosphorylation, promoting the formation and progression of pulmonary fibrosis.
  • Targeting the GSK3β/eEF2K pathway with inhibitors like TDZD-8 demonstrates therapeutic potential for mitigating pulmonary fibrosis and lung tissue damage.